In Depth 13 Mar 2024
From LSD to healing minds: Where are we standing in psychedelic drug development?
Delve into the growing sector of psychedelic drug development to find out where we are coming from, and where we are standing in the field.
mental health issues
- Latest Posts
Best in Biotech 30 Jan 2024
Navigating German biotech: 13 key players to know
The German biotech ecosystem is well established despite the challenges it is facing. Discover thirteen key Germany-based biotech companies.
Best in Biotech 25 Jan 2024
Eight mental health biotech companies trying to make a difference to people’s lives
Take a closer look at eight mental health companies developing therapies that could make a different to people with mental illnesses.
Best in Biotech 16 Jan 2024
Five biotech companies taking Florida by storm
Check out five of the top Florida companies taking the state’s biotech industry by storm with their innovative technologies.
In Depth 23 May 2023
New antidepressants: tackling treatment resistant depression
Depression is thought to affect approximately 5% of adults worldwide. It encompasses several different depressive disorders, including major depressive disorder, seasonal affective disorder, and persistent depressive disorder, all of which can bring enormous difficulty to people’s lives, resulting in symptoms like poor concentration, hopelessness about the future, feeling tired or low in energy, and suicidal […]
News and Trends 2 May 2023
Schizophrenia injection gets FDA approval
Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd., and MedinCell have announced the U.S. Food and Drug Administration (FDA) has approved UZEDY (risperidone) extended-release injectable suspension for the treatment of schizophrenia in adults. UZEDY is the first subcutaneous, long-acting formulation of risperidone that utilizes SteadyTeq, a copolymer technology proprietary to MedinCell that controls […]
ADVERTISEMENT
ADVERTISEMENT
News and Trends 21 Mar 2023
Karuna Therapeutics sees positive schizophrenia trial results
Karuna Therapeutics, Inc. has announced positive topline results from its phase 3 EMERGENT-3 trial evaluating the efficacy, safety, and tolerability of its lead investigational therapy, KarXT (xanomeline-trospium) in adults with schizophrenia. The trial met its primary endpoint, with KarXT demonstrating a statistically significant and clinically meaningful 8.4-point reduction in positive and negative syndrome scale (PANSS) […]
News and Trends 21 Mar 2023
Campbell Neurosciences creates saliva-based test for suicidal thoughts
Therapeutic Solutions International (TSOI) has announced that its spin-off biotech company, Campbell Neurosciences, Inc., obtained successful validation of its suicidal ideation predictive test using a saliva-based system. Previously, the company reported successful stratification of suicidal tendencies using a proprietary blood-based biomarker. In the trial, the company previously assessed levels of the inflammatory marker in 10 […]
News and Trends 16 Feb 2023
Newron reports ‘striking’ schizophrenia study results
Newron Pharmaceuticals S.p.A. has announced what it says are ‘very exciting new results’ from the first 100 randomized patients who have completed one year of treatment in its study of evenamide as an add-on to an antipsychotic (excluding clozapine) in patients with moderate to severe treatment-resistant schizophrenia (TRS) not responding to their current antipsychotic medication. […]
News and Trends 3 Jan 2023
Newron announces interim results from treatment-resistant schizophrenia trial
Newron Pharmaceuticals S.p.A. has announced what it says are “very compelling new results” from the first 100 enrolled patients to have reached the six-month timepoint in its international study of evenamide as an add-on to an antipsychotic (excluding clozapine) in patients with moderate to severe treatment-resistant schizophrenia (TRS), who were not responding to their current […]
News and Trends 15 Nov 2022
Potential new lead compounds for treatment of depression and anxiety disorders
Currently, various classes of drugs are available for the treatment of mental illnesses – such as depression and anxiety disorders. However, although these drugs have benefits, they can also be associated with adverse side-effects. A research group has conducted a study to identify new drugs that could potentially be used for the treatment of neuropsychiatric […]
More News! 9 Nov 2022
Sensorium closes $30M deal to advance drug discovery engine
Sensorium Therapeutics, announced the closing of a $30 million series a financing to advance its initial asset, SENS-01, and Biodynamic Discovery Platform (BDP). The platform is a drug discovery engine that rapidly identifies, synthesizes, and enhances targeted molecules as therapeutics. The round was led by Santé Ventures, a specialized healthcare and life sciences investment firm […]
ADVERTISEMENT